Vera Hárs

5.7k total citations · 2 hit papers
37 papers, 3.2k citations indexed

About

Vera Hárs is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Vera Hárs has authored 37 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 17 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Vera Hárs's work include Acute Myeloid Leukemia Research (10 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Cancer Treatment and Pharmacology (5 papers). Vera Hárs is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Cancer Treatment and Pharmacology (5 papers). Vera Hárs collaborates with scholars based in United States, Hungary and Austria. Vera Hárs's co-authors include Susan Halabi, Stephen L. George, Nicholas J. Vogelzang, David M. Brizel, Leonard R. Prosnitz, Andrew T. Huang, Richard L. Scher, Samuel R. Fisher, William J. Richtsmeier and Eric P. Winer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Vera Hárs

37 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

1998 883 citations David M. Brizel, Samuel R. Fisher et al. New England Journal of Medicine profile →
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

1999 694 citations Philip W. Kantoff, Susan Halabi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vera Hárs United States	19	1.4k	1.1k	774	655	523	37	3.2k
Qin Li China	31	1.2k 0.8×	1.3k 1.2×	405 0.5×	495 0.8×	1.1k 2.2×	154	3.9k
Tom Boterberg Belgium	36	1.3k 0.9×	1.2k 1.1×	905 1.2×	1.1k 1.7×	762 1.5×	167	4.2k
Bhupendra Rawal United States	26	705 0.5×	958 0.9×	52 0.1×	645 1.0×	705 1.3×	76	2.9k
Heath D. Skinner United States	38	1.3k 0.9×	1.6k 1.5×	755 1.0×	1.1k 1.6×	1.5k 2.8×	159	4.4k
Tetsuzo Tagawa Japan	33	1.3k 1.0×	1.3k 1.2×	85 0.1×	493 0.8×	543 1.0×	193	3.4k
Jerry J. Jaboin United States	25	350 0.3×	457 0.4×	94 0.1×	244 0.4×	869 1.7×	110	2.2k
Theodore Karrison United States	26	486 0.4×	1.1k 1.0×	39 0.1×	507 0.8×	927 1.8×	64	2.6k
Yutaka Fujiwara Japan	38	1.8k 1.3×	2.7k 2.4×	36 0.0×	596 0.9×	1.6k 3.0×	257	5.1k
P. Savvides United States	20	406 0.3×	734 0.7×	307 0.4×	285 0.4×	455 0.9×	89	1.7k
Jiayi Huang United States	33	963 0.7×	830 0.8×	80 0.1×	334 0.5×	796 1.5×	193	3.3k

Countries citing papers authored by Vera Hárs

Since Specialization

Citations

This map shows the geographic impact of Vera Hárs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vera Hárs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vera Hárs more than expected).

Fields of papers citing papers by Vera Hárs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vera Hárs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vera Hárs. The network helps show where Vera Hárs may publish in the future.

Co-authorship network of co-authors of Vera Hárs

This figure shows the co-authorship network connecting the top 25 collaborators of Vera Hárs. A scholar is included among the top collaborators of Vera Hárs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vera Hárs. Vera Hárs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vij, Ravi, Jennifer Le‐Rademacher, Kristina Laumann, et al.. (2019). A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biology of Blood and Marrow Transplantation. 25(10). 1984–1992. 23 indexed citations

Holstein, Sarah A., Kouros Owzar, Paul G. Richardson, et al.. (2015). Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).. Journal of Clinical Oncology. 33(15_suppl). 8523–8523. 16 indexed citations

Vij, Ravi, Vera Hárs, William Blum, et al.. (2014). CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure. Blood. 124(21). 543–543. 7 indexed citations

Kolitz, Jonathan E., Stephen L. George, Don M. Benson, et al.. (2013). Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer. 120(7). 1010–1017. 20 indexed citations

Shapiro, Charles L., Susan Halabi, Vera Hárs, et al.. (2011). Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. European Journal of Cancer. 47(5). 683–689. 81 indexed citations

McCarthy, Phillip, Kouros Owzar, K. C. Anderson, et al.. (2010). Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.. Journal of Clinical Oncology. 28(15_suppl). 8017–8017. 55 indexed citations

Kolitz, Jonathan E., Stephen L. George, Guido Marcucci, et al.. (2010). P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 116(9). 1413–1421. 90 indexed citations

Grinblatt, David L., Daohai Yu, Vera Hárs, et al.. (2008). Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan. Cancer. 115(1). 84–93. 5 indexed citations

Stone, Richard M., Kathleen Donohue, Wendy Stock, et al.. (2008). A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemotherapy and Pharmacology. 63(5). 859–864. 28 indexed citations

10.

George, Stephen L., Thomas J. Polascik, D. Albala, et al.. (2007). Impact of flaxseed supplementation and dietary fat restriction on prostate cancer proliferation and other biomarkers: Results of a Phase II randomized controlled trial (RCT) using a presurgical model. Journal of Clinical Oncology. 25(18_suppl). 1510–1510. 1 indexed citations

11.

Demark‐Wahnefried, Wendy, et al.. (1999). Utility of Produce Ratios to Track Fruit and Vegetable Consumption in a Rural Community, Church-Based 5 A Day Intervention Project. Nutrition and Cancer. 33(2). 213–217. 7 indexed citations

12.

Kantoff, Philip W., Susan Halabi, Mark R. Conaway, et al.. (1999). Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study. Journal of Clinical Oncology. 17(8). 2506–2506. 694 indexed citations breakdown →

13.

Kantoff, Philip W., Susan Halabi, Mark Conaway, et al.. (1999). HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182. The Journal of Urology. 176–176. 13 indexed citations

14.

Brizel, David M., Samuel R. Fisher, Richard L. Scher, et al.. (1998). Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. New England Journal of Medicine. 338(25). 1798–1804. 883 indexed citations breakdown →

15.

Dewhirst, Mark W., et al.. (1998). Artificial Neural Network Model of Survival in Patients Treated With Irradiation With and Without Concurrent Chemotherapy for Advanced Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 41(2). 339–345. 33 indexed citations

16.

Demark‐Wahnefried, Wendy, et al.. (1997). Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. American Journal of Clinical Nutrition. 65(5). 1495–1501. 160 indexed citations

17.

Demark‐Wahnefried, Wendy, et al.. (1997). Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.. Rehabilitation Oncology. 15(3). 21–21. 3 indexed citations

18.

Hussein, Atif, Maureen Ross, James J. Vredenburgh, et al.. (1995). Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous Done marrow after high‐dose chemotherapy. European Journal Of Haematology. 54(5). 281–287. 18 indexed citations

19.

Hussein, Atif, Maureen Ross, James J. Vredenburgh, et al.. (1995). Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high‐dose chemotherapy. European Journal Of Haematology. 55(5). 348–356. 12 indexed citations

20.

Daly, L., John Ferguson, Vera Hárs, et al.. (1992). Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.. Journal of Clinical Oncology. 10(7). 1057–1065. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact